(Q45798777)

English

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells

scientific article published on 25 April 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

toll-like receptor

0 references

5

object named as

Steven G Reed

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

author name string

Laura P Schneider

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Antoinet J Schoonderwoerd

2

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Magdalini Moutaftsi

3

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Randall F Howard

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Esther C de Jong

6

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Marcel B M Teunissen

7

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

language of work or name

0 references

publication date

25 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

30

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

28

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

4216-4224

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

Vaccinology at the beginning of the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Tolerogenic dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Toll-like receptors control activation of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Optimized subunit vaccine protects against experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cutaneous dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Down-regulation of Toll-like receptor expression in monocyte-derived Langerhans cell-like cells: implications of low-responsiveness to bacterial components in the epidermal Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Microbial Compounds Selectively Induce Th1 Cell-Promoting or Th2 Cell-Promoting Dendritic Cells In Vitro with Diverse Th Cell-Polarizing Signals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Keratinocytes and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Cytokines and chemokines in the epidermis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.051

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.04.051

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/22542815

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45798777&oldid=2083244544"